Target intelligence / Profile preview

Tumor necrosis factor receptor superfamily member 9 (4-1BB) intracellular costimulatory domain (4-1BB ICD)

Target
4-1BB ICD
Molecular classification
Tumor necrosis factor receptor superfamily, Costimulatory signaling domain, Synthetic receptor component
01

Overview

The Tumor necrosis factor receptor superfamily member 9 (TNFRSF9), commonly known as 4-1BB or CD137, is a surface glycoprotein that functions as a potent costimulatory member of the TNF receptor family (UniProt: Q07011). In the design of second and third-generation Chimeric Antigen Receptors (CARs), the intracellular costimulatory domain (ICD) of 4-1BB is utilized to provide the necessary secondary signal for robust T-cell activation and longevity (PubMed: 28933255). Unlike CD28-based CARs, which often lead to rapid effector differentiation and exhaustion, the 4-1BB ICD promotes mitochondrial biogenesis and oxidative metabolism, favoring the development of central memory T-cells and long-term persistence in vivo (PubMed: 27226537). \n\nThis domain operates by recruiting Tumor Necrosis Factor Receptor-Associated Factors (TRAFs), specifically TRAF1 and TRAF2, which trigger downstream NF-kappaB and MAPK/ERK signaling pathways (PubMed: 30206110). Clinically, the 4-1BB ICD is a core component of several approved therapies, such as Tisagenlecleucel and Lisocabtagene maraleucel, where it is critical for achieving sustained remission in B-cell malignancies (FDA Label: Kymriah, Breyanzi). While it generally exhibits a safer toxicity profile with slower expansion kinetics than CD28, it is still associated with significant risks like cytokine release syndrome (CRS) and neurotoxicity (PubMed: 29937173).

Other names
4-1BBCD137TNFRSF9Induced by lymphocyte activationILACDw137T-cell antigen 4-1BB homolog
02

Mechanism of action

The 4-1BB intracellular costimulatory domain functions by recruiting Tumor Necrosis Factor Receptor-Associated Factors (TRAFs), primarily TRAF1 and TRAF2, which assemble signaling complexes that activate the NF-kappaB, c-Jun N-terminal kinase (JNK), and p38 MAPK pathways. In the context of a Chimeric Antigen Receptor (CAR), this signaling provides "Signal 2", which complements the "Signal 1" from the CD3-zeta domain to promote T-cell survival, metabolic reprogramming toward oxidative phosphorylation, and the formation of long-lived memory T-cells (PubMed: 28933255, PubMed: 27226537).

03

Biological functions

T-cell activationT-cell survivalMitochondrial biogenesisMemory T-cell formationNF-kappaB signalingMetabolic reprogramming
04

Disease associations

B-cell lymphomaAcute lymphoblastic leukemiaMultiple myelomaChronic lymphocytic leukemia
05

Safety considerations

Cytokine release syndrome (CRS)Immune effector cell-associated neurotoxicity syndrome (ICANS)On-target off-tumor toxicityPotential for tonic signaling leading to premature exhaustion
06

Interacting drugs

Tisagenlecleucel

3 more in the full profile.

07

Biomarkers

CAR-T cell expansion (Cmax)CAR-T cell persistence (AUC)Proportion of CD8+ central memory T-cells (Tcm)Serum cytokine profiles (e.g., IL-6, IFN-gamma)

Beyond the preview

Go deeper on Tumor necrosis factor receptor superfamily member 9 (4-1BB) intracellular costimulatory domain (4-1BB ICD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor necrosis factor receptor superfamily member 9 (4-1BB) intracellular costimulatory domain (4-1BB ICD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call